Gyre Therapeutics Inc. Earnings

The next earnings date for Gyre Therapeutics Inc. has not yet been scheduled.

Analyst Estimates of Gyre Therapeutics Inc. Earnings

No results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Gyre Therapeutics Inc. Earnings: Historical

11/05/2026After Market$0.04126.67%
08/07/2026---$-0.12-50.00%
05/07/2026Before Market$-0.10-42.86%
03/31/2026---$0.050.21%
11/07/2025Before Market$0.03250.00%
08/11/2025After Market$0.00-92.67%
05/09/2025Before Market$0.00-85.67%
03/24/2025Before Market$-0.00-102.75%
11/04/2024After Market$0.01---
08/12/2024Before Market$0.03---
...

More About Gyre Therapeutics Inc.

Country
USA
Full Time Employees
625

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

“Gyre Therapeutics Inc. Earnings” Can Refer to the Gyre Therapeutics Inc. Earnings Date

Some people say “Gyre Therapeutics Inc. earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Gyre Therapeutics Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Gyre Therapeutics Inc. Stock on the Earnings Date

If you own Gyre Therapeutics Inc. stock (GYRE) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Gyre Therapeutics Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Gyre Therapeutics Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Gyre Therapeutics Inc. Earnings

You can contact us any time if you would like to ask questions about Gyre Therapeutics Inc. earnings or anything else related to the stock market.